BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hu Y, Zhu Y, Lu NH. Recent progress in Helicobacter pylori treatment. Chin Med J (Engl). 2020;133:335-343. [PMID: 31929363 DOI: 10.1097/cm9.0000000000000618] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Prada CF, Casadiego MA, Freire CC. Evolution of Helicobacter spp: variability of virulence factors and their relationship to pathogenicity. PeerJ 2022;10:e13120. [DOI: 10.7717/peerj.13120] [Reference Citation Analysis]
2 Cho JH, Jin SY. Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea. World J Clin Cases 2022; 10(19): 6349-6359 [DOI: 10.12998/wjcc.v10.i19.6349] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ouyang Y, Wang M, Xu YL, Zhu Y, Lu NH, Hu Y. Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: A systematic review and meta-analysis. J Gastroenterol Hepatol 2022. [PMID: 35716370 DOI: 10.1111/jgh.15917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Jin F, Yang H. Transcriptome Analysis of the Response of Mature Helicobacter pylori Biofilm to Different Doses of Lactobacillus salivarius LN12 with Amoxicillin and Clarithromycin. Antibiotics 2022;11:262. [DOI: 10.3390/antibiotics11020262] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Cai X, Li X, Jin Y, Zhang M, Xu Y, Liang C, Weng Y, Yu W, Li X. Vitamins and Helicobacter pylori: An Updated Comprehensive Meta-Analysis and Systematic Review. Front Nutr 2022;8:781333. [DOI: 10.3389/fnut.2021.781333] [Reference Citation Analysis]
6 Lai Y, Wei W, Du Y, Gao J, Li Z. Biomaterials for Helicobacter pylori therapy: therapeutic potential and future perspectives. Gut Microbes 2022;14:2120747. [PMID: 36070564 DOI: 10.1080/19490976.2022.2120747] [Reference Citation Analysis]
7 Zhang X, Sang S, Guan Q, Tao H, Wang Y, Liu C. Identification of B-Cell Epitopes of HspA from Helicobacter pylori and Detection of Epitope Antibody Profiles in Naturally Infected Persons. Vaccines (Basel) 2021;10:65. [PMID: 35062726 DOI: 10.3390/vaccines10010065] [Reference Citation Analysis]
8 Penumetcha SS, Ahluwalia S, Irfan R, Khan SA, Rohit Reddy S, Vasquez Lopez ME, Zahid M, Busmail A, Mohammed L. The Efficacy of Probiotics in the Management of Helicobacter Pylori: A Systematic Review. Cureus 2021;13:e20483. [PMID: 35047301 DOI: 10.7759/cureus.20483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Krzyżek P, Junka A, Słupski W, Dołowacka-Jóźwiak A, Płachno BJ, Sobiecka A, Matkowski A, Chodaczek G, Płusa T, Gościniak G, Zielińska S. Antibiofilm and Antimicrobial-Enhancing Activity of Chelidonium majus and Corydalis cheilanthifolia Extracts against Multidrug-Resistant Helicobacter pylori. Pathogens 2021;10:1033. [PMID: 34451497 DOI: 10.3390/pathogens10081033] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
10 Mladenova I. Clinical Relevance of Helicobacter pylori Infection. J Clin Med 2021;10:3473. [PMID: 34441769 DOI: 10.3390/jcm10163473] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
11 Jin F, Yang H. Effects of Lactobacillus salivarius LN12 in Combination with Amoxicillin and Clarithromycin on Helicobacter pylori Biofilm In Vitro. Microorganisms 2021;9:1611. [PMID: 34442690 DOI: 10.3390/microorganisms9081611] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
12 Yang H, Hu B. Diagnosis of Helicobacter pylori Infection and Recent Advances. Diagnostics (Basel) 2021;11:1305. [PMID: 34441240 DOI: 10.3390/diagnostics11081305] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
13 Gao W, Zhang X, Yin Y, Yu S, Wang L. Different dose of new generation proton pump inhibitors for the treatment of Helicobacter pylori infection: A meta-analysis. Int J Immunopathol Pharmacol 2021;35:20587384211030397. [PMID: 34250840 DOI: 10.1177/20587384211030397] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Kuo CF, Shi L, Lin CL, Yao WC, Chen HT, Lio CF, Wang YT, Su CH, Hsu NW, Tsai SY. How peptic ulcer disease could potentially lead to the lifelong, debilitating effects of chronic fatigue syndrome: an insight. Sci Rep 2021;11:7520. [PMID: 33824394 DOI: 10.1038/s41598-021-87018-z] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
15 Sánchez-Alonzo K, Belmar L, Parra-Sepúlveda C, Bernasconi H, Campos VL, Smith CT, Sáez K, García-Cancino A. Antibiotics as a Stressing Factor Triggering the Harboring of Helicobacter pylori J99 within Candida albicans ATCC10231. Pathogens 2021;10:382. [PMID: 33806815 DOI: 10.3390/pathogens10030382] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Ye ZN, Xia HH, Zhang R, Li L, Wu LH, Liu XJ, Xie WR, He XX. The Efficacy of Washed Microbiota Transplantation on Helicobacter pylori Eradication: A Pilot Study. Gastroenterol Res Pract 2020;2020:8825189. [PMID: 33133183 DOI: 10.1155/2020/8825189] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
17 Krzyżek P, Paluch E, Gościniak G. Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-Resistant Helicobacter pylori. Antibiotics (Basel) 2020;9:E658. [PMID: 33007899 DOI: 10.3390/antibiotics9100658] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
18 Yan TL, Gao JG, Wang JH, Chen D, Lu C, Xu CF. Current status of Helicobacter pylori eradication and risk factors for eradication failure. World J Gastroenterol 2020; 26(32): 4846-4856 [PMID: 32921961 DOI: 10.3748/wjg.v26.i32.4846] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
19 Mascellino MT, Oliva A, Miele MC, De Angelis M, Bruno G, Severi C. Secondary Antibiotic Resistance, Correlation between Genotypic and Phenotypic Methods and Treatment in Helicobacter pylori Infected Patients: A Retrospective Study. Antibiotics (Basel) 2020;9:E549. [PMID: 32872117 DOI: 10.3390/antibiotics9090549] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
20 Duda-Madej A, Kozłowska J, Krzyżek P, Anioł M, Seniuk A, Jermakow K, Dworniczek E. Antimicrobial O-Alkyl Derivatives of Naringenin and Their Oximes Against Multidrug-Resistant Bacteria. Molecules 2020;25:E3642. [PMID: 32785151 DOI: 10.3390/molecules25163642] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
21 Song Z, Li B, Zhang Y, Li R, Ruan H, Wu J, Liu Q. Outer Membrane Vesicles of Helicobacter pylori 7.13 as Adjuvants Promote Protective Efficacy Against Helicobacter pylori Infection. Front Microbiol 2020;11:1340. [PMID: 32733396 DOI: 10.3389/fmicb.2020.01340] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]